MediWound Ltd. (NASDAQ:MDWD) Receives Average Recommendation of “Moderate Buy” from Brokerages

MediWound Ltd. (NASDAQ:MDWD) has earned an average rating of “Moderate Buy” from the six ratings firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $33.50.

Several brokerages recently weighed in on MDWD. Wall Street Zen upgraded shares of MediWound from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Zacks Research upgraded shares of MediWound from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of MediWound in a research report on Thursday, January 22nd. Finally, HC Wainwright restated a “buy” rating and issued a $36.00 target price (up from $31.00) on shares of MediWound in a research report on Friday, November 21st.

Hedge Funds Weigh In On MediWound

Institutional investors and hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets raised its position in shares of MediWound by 90.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 723 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in MediWound by 69.1% during the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 649 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in MediWound by 22.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 999 shares during the period. Deutsche Bank AG lifted its position in MediWound by 79.6% in the fourth quarter. Deutsche Bank AG now owns 7,971 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 3,532 shares during the period. Finally, Hudson Bay Capital Management LP bought a new position in MediWound during the 3rd quarter valued at $180,000. Institutional investors own 46.83% of the company’s stock.

MediWound Price Performance

Shares of MDWD opened at $17.25 on Thursday. MediWound has a 12 month low of $14.14 and a 12 month high of $22.50. The stock has a fifty day moving average price of $18.13 and a 200 day moving average price of $18.01. The company has a market cap of $221.49 million, a P/E ratio of -9.08 and a beta of 0.13.

MediWound (NASDAQ:MDWD) last posted its earnings results on Thursday, November 20th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.57. MediWound had a negative return on equity of 62.11% and a negative net margin of 98.43%.The company had revenue of $5.43 million for the quarter, compared to analysts’ expectations of $6.56 million. As a group, research analysts anticipate that MediWound will post -2.66 earnings per share for the current year.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.